Journal article
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada
Abstract
AIMS: There are no direct comparisons of the relative cost-effectiveness of second-generation anti-androgens (enzalutamide and apalutamide) used in managing metastatic castration-sensitive prostate cancer (mCSPC) in Canada. This study compared the cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy (ADT) alone (standard of care) in patients with mCSPC from the Canadian public payer perspective using a …
Authors
Saad F; Chilelli A; Hui B; Muratov S; Ganguli A; North S; Shayegan B
Journal
Journal of Medical Economics, Vol. 25, No. 1, pp. 583–590
Publisher
Taylor & Francis
Publication Date
December 31, 2022
DOI
10.1080/13696998.2022.2066850
ISSN
1369-6998